

**AMENDMENTS TO THE CLAIMS**

Claims 1-154 are cancelled.

Claim 155 (previously presented): An isolated antigen-binding fragment comprising a polypeptide domain that specifically binds a BDCA-2 protein encoded by SEQ ID NO:1, wherein said BDCA-2 protein is encoded by exons 1-6; exons 1 and 3-6; exons 1-2 and 4-6; or exons 1-3 and 5-6 of SEQ ID NO:1.

Claim 156 (previously presented): The antigen-binding fragment of claim 155 that is a monoclonal antibody comprising two heavy and two light chains.

Claim 157 (previously presented): The antigen-binding fragment of claim 156 wherein the antibody is human, murine, humanized or a bispecific antibody.

Claim 158 (previously presented): The antigen-binding fragment of claim 155 that is a Fab, F(ab')<sub>2</sub>, scFv, or fusion polypeptide, or is encoded by a phage display library.

Claim 159 (previously presented): The antigen-binding fragment of claim 155 wherein the BDCA-2 protein is glycosylated.

Claim 160 (cancelled):

Claim 161 (previously presented): The antigen-binding fragment of any of claims 155-159 that is conjugated to a chemically functional moiety.

Claim 162 (previously presented): The antigen-binding fragment of claim 161 wherein the chemically functional moiety is selected from the group consisting of a radioisotope, fluorescent

compound, chemiluminescent compound, bioluminescent compound, enzyme, and a paramagnetic label.

Claim 163 (previously presented): The antigen-binding fragment of any of claims 155-159 that is bound to a BDCA-2 protein.

Claim 164 (previously presented): An antigen-binding fragment of any of claims 155-159 that is bound to a cell that expresses a BDCA-2 protein.

Claim 165 (previously presented): The antigen-binding fragment of claim 164 wherein the cell is a dendritic cell.

Claim 166 (previously presented): The antigen-binding fragment of claim 165 wherein the dendritic cell is BDCA-4<sup>+</sup>.

Claim 167 (previously presented): The antigen-binding fragment of claim 166 wherein the dendritic cell is human.

Claim 168 (withdrawn): The antigen-binding fragment of claim 165 wherein an anti-BDCA-4 antibody is also bound to the dendritic cell.

Claim 169 (previously presented): A composition comprising the antigen-binding fragment of claim 155 composition and a pharmaceutically acceptable excipient.

Claim 170 (previously presented): An isolated cell that produces an antigen-binding fragment of claim 155.

Claim 171 (previously presented): A hybridoma that produces an antigen-binding fragment of claim 156.

Claim 172 (withdrawn): A method for preparing a population of cells enriched for BDCA-2<sup>+</sup> cells, comprising contacting a mixture of human cells with an antigen-binding fragment of claim 155 and isolating cells to which the antigen-binding fragment binds.

Claim 173 (withdrawn): A method of detecting BDCA-2 protein in a biological sample comprising (a) contacting the BDCA-2 protein with the antigen-binding fragment thereof of claim 155 under conditions that permit formation of a complex between the BDCA-2 protein and the antigen-binding fragment; and (b) detecting the formation of the complex.

Claim 174 (withdrawn): The method of claim 173 wherein the BDCA-2 protein is displayed on the surface of a dendritic cell.

Claim 175 (withdrawn): The method of claim 174 wherein the step of detecting the formation of the complex comprises detecting at least one metabolic change in the dendritic cell.

Claim 176 (withdrawn): The method of claim 175 wherein the metabolic change is down-regulation of type I interferon production, down-regulation of Th1 immune responses, induction of intracellular Ca<sup>2+</sup> mobilization, or polarization of an immune response to Th2.

Claim 177 (withdrawn): A method of ligating BDCA-2 antigen on a dendritic cell comprising contacting the cell with the antigen-binding fragment of claim 155.

Claim 178 (withdrawn): A method of screening for agents that interfere with ligation of BDCA-2, said method comprising contacting a BDCA-2 protein and an antigen-binding fragment of claim 155 in the presence of a test agent and determining whether the test agent reduces binding of the antigen-binding fragment to the protein.

Claim 179 (Currently Amended): A kit comprising an antigen-binding fragment of claim 155 and a component selected from the group consisting of: ~~BDCA-2 protein~~, a buffer, and a label conjugated to, or that can be conjugated to, the antigen-binding fragment.